Binding of the Hemopressin Peptide to the Cannabinoid CB1 Receptor: Structural Insights

详细信息    查看全文

• 作者：Mario Scrima ; Sara Di Marino ; Manuela Grimaldi ; Antonia Mastrogiacomo ; Ettore Novellino ; Maurizio Bifulco ; Anna Maria D’ ; Ursi
• 刊名：Biochemistry
• 出版年：2010
• 出版时间：December 14, 2010
• 年：2010
• 卷：49
• 期：49
• 页码：10449-10457
• 全文大小：1033K
• 年卷期：v.49,no.49(December 14, 2010)
• ISSN：1520-4995

文摘

Hemopressin, a bioactive nonapeptide derived from the α1 chain of hemoglobin, was recently shown to possess selective antagonist activity at the cannabinoid CB₁ receptor [Heimann, A. S., et al. (2007) Proc. Natl. Acad. Sci. U.S.A. 104, 20588−20593]. CB₁ receptor antagonists have been extensively studied for their possible therapeutic use in the treatment of obesity, drug abuse, and heroin addiction. In particular, many compounds acting as CB₁ receptor antagonists have been synthesized and subjected to experiments as possible anti-obesity drugs, but their therapeutic application is still complicated by important side effects. Using circular dichroism and nuclear magnetic resonance spectroscopy, this work reports the conformational analysis of hemopressin and its truncated, biologically active fragment hemopressin(1−6). The binding modes of both hemopressin and hemopressin(1−6) are investigated by molecular docking calculations. Our conformational data indicate that regular turn structures in the central portion of hemopressin and hemopressin(1−6) are critical for an effective interaction with the receptor. The results of molecular docking calculations, indicating similarities and differences in comparison to the most accepted CB₁ pharmacophore model, suggest the possibility of new chemical scaffolds for the design of new CB₁ antagonist lead compounds.